Health
Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity
Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10 (41.4%) achieving 25% or more weight loss1.Substantial weight loss was consistent across all menopausal stages, as well as major reductions in waist circumference, a key indicator of metabolic health1.Women taking Wegovy® had an average 42–45% lower risk of migraine starting six months after initiation, and a 25% lower risk of depression, compared with menopausal hormone therapy alone2. Bagsv
About this update from Novo Nordisk A/s Class B
[{"type":"image","alt":"Novo Nordisk A/S","displaySize":"","headline":null,"caption":"Novo Nordisk A/S","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":214,"url":"https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/GU8RSeYXqJzkiM2VxLxQ7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMwMA--/https://media.zenfs.com/en/globenewswire.com/b199128d4b2bbea4504ed4a2f3b29b4e","width":300,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Wegovy® showed an average 22.6% weight loss for premenopausal women with obesity, with more than 4 in 10 (41.4%) achieving 25% or more weight loss1.","length":148,"tagName":"p"}]},{"val":[{"type":"text","content":"Substantial weight loss was consistent across all menopausal stages, as well as major reductions in waist circumference, a key indicator of metabolic health1.","length":158,"tagName":"p"}]},{"val":[{"type":"text","content":"Women taking Wegovy® had an average 42–45% lower risk of migraine starting six months after initiation, and a 25% lower risk of depression, compared with menopausal hormone therapy alone2.","length":188,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":494,"olType":false},{"type":"text","content":"Bagsværd, Denmark, 12 May 2026 – Novo Nordisk today announced data demonstrating that Wegovy® (semaglutide 2.4 mg and 7.2 mg) delivers substantial and consistent weight-loss results for women with obesity across reproductive life stages, from premenopausal years through the menopause transition and beyond1. The menopausal stages are perimenopause (the transition phase), menopause and postmenopause (after menopause).","length":419,"tagName":"p"},{"type":"text","content":"The findings are based on the STEP UP clinical weight management trial, the landmark SELECT clinical cardiovascular trial and one large-scale real-world evidence study, all presented at the European Congress on Obesity (ECO) 2026 in Istanbul, Türkiye1-3. The studies show that when women with obesity lose weight with semaglutide, they improve their body composition with r...